Related Experiment Videos
Diabetes vaccines: a future to be realized
K Lin-Su1, A Kukreja, N K Maclaren
1Department of Pediatric Endocrinology, Weill Medical College of Cornell University, New York, New York 10021, USA.
Diabetes Technology & Therapeutics
|January 5, 2002
Summary
New antigen-based therapies, including vaccines, offer a promising approach to restore immune tolerance and treat immune-mediated diabetes by targeting its autoimmune cause.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Immune-mediated diabetes mellitus (IMD) involves chronic autoimmune destruction of pancreatic islet cells by T lymphocytes.
- Current diabetes management has limitations in addressing the disease's root cause.
- Understanding IMD immunopathogenesis is crucial for developing targeted interventions.
Purpose of the Study:
- To explore the pathogenesis of IMD in relation to therapeutic strategies.
- To review intervention strategies for IMD, particularly antigen-based therapies.
- To present recent advancements in human trials for IMD intervention and prevention.
Main Methods:
- Review of IMD pathogenesis and immunopathogenesis.
- Analysis of therapeutic intervention strategies, including altered peptide ligands (APLs) and vaccines.
- Examination of data from rodent models and human clinical trials.
Main Results:
- Antigen-based therapies, such as APLs and vaccines, show potential for restoring immune tolerance.
- Non-immunosuppressive strategies aim to boost regulatory immune function rather than broadly suppress it.
- Early human trials indicate promise for vaccine prototypes in diabetes intervention and prevention.
Conclusions:
- Antigen-specific vaccines and immunostimulants represent a novel therapeutic avenue for IMD.
- Restoring self-tolerance through targeted immune modulation is a key goal.
- Further research and clinical trials are essential to validate these promising strategies for type 1 diabetes.